請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79056
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡錦華 | zh_TW |
dc.contributor.advisor | Ching-Hwa Tsai | en |
dc.contributor.author | 楊宜瑾 | zh_TW |
dc.contributor.author | Yi-Chin Yang | en |
dc.date.accessioned | 2021-07-11T15:40:16Z | - |
dc.date.available | 2024-02-28 | - |
dc.date.copyright | 2018-10-09 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | Adamson, A.L., Darr, D., Holley-Guthrie, E., Johnson, R.A., Mauser, A., Swenson, J., and Kenney, S. (2000). Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74, 1224-1233.
Bachelet, I., Munitz, A., and Levi-Schaffer, F. (2006). Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 117, 1314-1320. Bachelet, I., Munitz, A., Moretta, A., Moretta, L., and Levi-Schaffer, F. (2005). The Inhibitory Receptor IRp60 (CD300a) Is Expressed and Functional on Human Mast Cells. The Journal of Immunology 175, 7989-7995. Baer, R., Bankier, A.T., Biggin, M.D., Deininger, P.L., Farrell, P.J., Gibson, T.J., Hatfull, G., Hudson, G.S., Satchwell, S.C., Seguin, C., et al. (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211. Bentz, G.L., Moss, C.R., 2nd, Whitehurst, C.B., Moody, C.A., and Pagano, J.S. (2015). LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1. J Virol 89, 7465-7477. Borrego, F. (2013). The CD300 molecules: an emerging family of regulators of the immune system. Blood 121, 1951-1960. Burke, A.P., Yen, T.S., Shekitka, K.M., and Sobin, L.H. (1990). Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3, 377-380. Cantoni, C., Bottino, C., Augugliaro, R., Morelli, L., Marcenaro, E., Castriconi, R., Vitale, M., Pende, D., Sivori, S., Millo, R., et al. (1999). Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 29, 3148-3159. Carnec, X., Meertens, L., Dejarnac, O., Perera-Lecoin, M., Hafirassou, M.L., Kitaura, J., Ramdasi, R., Schwartz, O., and Amara, A. (2016). The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection. J Virol 90, 92-102. Chen, F. (2012). JNK-Induced Apoptosis, Compensatory Growth, and Cancer Stem Cells. Cancer Research 72, 379. Chen, Z., Shojaee, S., Buchner, M., Geng, H., Lee, J.W., Klemm, L., Titz, B., Graeber, T.G., Park, E., Tan, Y.X., et al. (2015). Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 521, 357-361. Clark, G.J., Ju, X., Tate, C., and Hart, D.N. (2009). The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol 30, 209-217. Cohen, J.I., Wang, F., and Kieff, E. (1991). Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65, 2545-2554. Cordier, M., Calender, A., Billaud, M., Zimber, U., Rousselet, G., Pavlish, O., Banchereau, J., Tursz, T., Bornkamm, G., and Lenoir, G.M. (1990). Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 64, 1002-1013. Countryman, J., and Miller, G. (1985). Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82, 4085-4089. DeBell, K.E., Simhadri, V.R., Mariano, J.L., and Borrego, F. (2012). Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a. BMC Immunol 13, 23. Dolyniuk, M., Pritchett, R., and Kieff, E. (1976). Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol 17, 935-949. Elliott Kieff, M.-S.K., Michael calderwood (2009). Chapter 14. Epstein-Barr Virus Latent Infection Nuclear Proteins: Genome Maintenance and Regulation of Lymphocyte Cell Growth and Survival, Vol 1. Epstein, M.A., Achong, B.G., and Barr, Y.M. (1964). Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1, 702-703. Feederle, R., Kost, M., Baumann, M., Janz, A., Drouet, E., Hammerschmidt, W., and Delecluse, H.J. (2000). The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19, 3080-3089. Fitzsimmons, L., and Kelly, G.L. (2017). EBV and Apoptosis: The Viral Master Regulator of Cell Fate? Viruses 9. Ghosh, D., and Kieff, E. (1990). cis-acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site. J Virol 64, 1855-1858. Given, D., Yee, D., Griem, K., and Kieff, E. (1979). DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol 30, 852-862. Goormachtigh, G., Ouk, T.S., Mougel, A., Tranchand-Bunel, D., Masy, E., Le Clorennec, C., Feuillard, J., Bornkamm, G.W., Auriault, C., Manet, E., et al. (2006). Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J Virol 80, 7382-7393. Gordadze, A.V., Peng, R., Tan, J., Liu, G., Sutton, R., Kempkes, B., Bornkamm, G.W., and Ling, P.D. (2001). Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J Virol 75, 5899-5912. Granato, M., Romeo, M.A., Tiano, M.S., Santarelli, R., Gonnella, R., Gilardini Montani, M.S., Faggioni, A., and Cirone, M. (2017). Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy. Sci Rep 7, 13052. Grauwet, K., Vitale, M., De Pelsmaeker, S., Jacob, T., Laval, K., Moretta, L., Parodi, M., Parolini, S., Cantoni, C., and Favoreel, H.W. (2016). Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a. J Virol 90, 1522-1533. Hammerschmidt, W., and Sugden, B. (1989). Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340, 393-397. Harada, S., and Kieff, E. (1997). Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 71, 6611-6618. Hardwick, J.M., Lieberman, P.M., and Hayward, S.D. (1988). A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62, 2274-2284. Harter, M.R., Liu, C.D., Shen, C.L., Gonzalez-Hurtado, E., Zhang, Z.M., Xu, M., Martinez, E., Peng, C.W., and Song, J. (2016). BS69/ZMYND11 C-Terminal Domains Bind and Inhibit EBNA2. PLoS Pathog 12, e1005414. Henkel, T., Ling, P.D., Hayward, S.D., and Peterson, M.G. (1994). Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265, 92-95. Hsieh, J.J., and Hayward, S.D. (1995). Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268, 560-563. Hutt-Fletcher, L.M. (2007). Epstein-Barr virus entry. J Virol 81, 7825-7832. Jiang, L., Xu, Y., Zeng, X., Fang, J., Morse, H.C., 3rd, and Zhou, J.X. (2015). Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget 6, 31191-31202. Jin, X.W., and Speck, S.H. (1992). Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J Virol 66, 2846-2852. Johannsen, E., Koh, E., Mosialos, G., Tong, X., Kieff, E., and Grossman, S.R. (1995). Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 69, 253-262. Johansson, B., Klein, G., Henle, W., and Henle, G. (1970). Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer 6, 450-462. Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., Sands, J., Gottman, D., Katz, B.Z., and Sklar, J. (1988). T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 318, 733-741. Jones, R.J., Seaman, W.T., Feng, W.H., Barlow, E., Dickerson, S., Delecluse, H.J., and Kenney, S.C. (2007). Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 121, 1274-1281. Ju, X., Zenke, M., Hart, D.N., and Clark, G.J. (2008). CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 112, 1184-1194. Jung, Y.J., Choi, H., Kim, H., and Lee, S.K. (2014). MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. J Virol 88, 9027-9037. Kempkes, B., and Ling, P.D. (2015). EBNA2 and Its Coactivator EBNA-LP. Curr Top Microbiol Immunol 391, 35-59. Knutson, J.C. (1990). The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 64, 2530-2536. Kuo, Y.C., Huang, K.Y., Yang, C.H., Yang, Y.S., Lee, W.Y., and Chiang, C.W. (2008). Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 283, 1882-1892. Lai, E.C. (2002). Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins. EMBO Rep 3, 840-845. Lai, K.Y., Chou, Y.C., Lin, J.H., Liu, Y., Lin, K.M., Doong, S.L., Chen, M.R., Yeh, T.H., Lin, S.J., and Tsai, C.H. (2015). Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cdelta Pathway. J Virol 89, 5968-5980. Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., and Hermoso, M.A. (2014). Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014, 149185. Lankry, D., Rovis, T.L., Jonjic, S., and Mandelboim, O. (2013). The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol 43, 2151-2161. Laux, G., Freese, U.K., and Bornkamm, G.W. (1985). Structure and evolution of two related transcription units of Epstein-Barr virus carrying small tandem repeats. J Virol 56, 987-995. Lee, M.A., Diamond, M.E., and Yates, J.L. (1999). Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol 73, 2974-2982. Li, Q., Spriggs, M.K., Kovats, S., Turk, S.M., Comeau, M.R., Nepom, B., and Hutt-Fletcher, L.M. (1997). Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 71, 4657-4662. Lin, J.C., Sista, N.D., Besencon, F., Kamine, J., and Pagano, J.S. (1991). Identification and functional characterization of Epstein-Barr virus DNA polymerase by in vitro transcription-translation of a cloned gene. J Virol 65, 2728-2731. Ling, P.D., Rawlins, D.R., and Hayward, S.D. (1993). The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci U S A 90, 9237-9241. Liu, P., Liu, S., and Speck, S.H. (1998). Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J Virol 72, 8230-8239. Liu, Y.R., Huang, S.Y., Chen, J.Y., and Wang, L.H. (2013). Microtubule depolymerization activates the Epstein-Barr virus lytic cycle through protein kinase C pathways in nasopharyngeal carcinoma cells. J Gen Virol 94, 2750-2758. Lu, F., Chen, H.S., Kossenkov, A.V., DeWispeleare, K., Won, K.J., and Lieberman, P.M. (2016). EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jkappa and EBF1. PLoS Pathog 12, e1005339. Luka, J., Kallin, B., and Klein, G. (1979). Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94, 228-231. Menezes, J., Leibold, W., and Klein, G. (1975). Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res 92, 478-484. Mercer, J., and Helenius, A. (2008). Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531-535. Morrison, T.E., and Kenney, S.C. (2004). BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 328, 219-232. Nalesnik, M.A. (1998). Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 20, 325-342. Nemerow, G.R., Mold, C., Schwend, V.K., Tollefson, V., and Cooper, N.R. (1987). Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 61, 1416-1420. Packard, T.A., and Cambier, J.C. (2013). B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Rep 5, 40. Purtilo, D.T. (1987). Epstein-Barr virus: the spectrum of its manifestations in human beings. South Med J 80, 943-947. Rickinson, A.B.K., E. (2007). Epstein‐Barr virus‐associated malignancies of the immunocompromised host. In Fields Virology, 5 edn, pp. 2668‐2700. Edited by D. M. K. a. P. M. Howley: Lippincott Williams & Wilkins. Robertson, E.S., Lin, J., and Kieff, E. (1996). The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70, 3068-3074. Silva, R., Moir, S., Kardava, L., Debell, K., Simhadri, V.R., Ferrando-Martinez, S., Leal, M., Pena, J., Coligan, J.E., and Borrego, F. (2011). CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection. Blood 117, 5870-5880. Simhadri, V.R., Andersen, J.F., Calvo, E., Choi, S.C., Coligan, J.E., and Borrego, F. (2012). Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119, 2799-2809. Skare, J., Farley, J., Strominger, J.L., Fresen, K.O., Cho, M.S., and zur Hausen, H. (1985). Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. J Virol 55, 286-297. Sui, X., Kong, N., Ye, L., Han, W., Zhou, J., Zhang, Q., He, C., and Pan, H. (2014). p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett 344, 174-179. Takada, K. (1984). Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 33, 27-32. Takada, K., and Ono, Y. (1989). Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63, 445-449. Thorley-Lawson, D.A., and Allday, M.J. (2008). The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6, 913-924. Thorley-Lawson, D.A., and Gross, A. (2004). Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350, 1328-1337. Tong, X., Yalamanchili, R., Harada, S., and Kieff, E. (1994). The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J Virol 68, 6188-6197. Tovey, M.G., Lenoir, G., and Begon-Lours, J. (1978). Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276, 270-272. Wang, F., Tsang, S.F., Kurilla, M.G., Cohen, J.I., and Kieff, E. (1990). Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64, 3407-3416. Young, L.S., and Rickinson, A.B. (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4, 757-768. Yue, W., Davenport, M.G., Shackelford, J., and Pagano, J.S. (2004). Mitosis-Specific Hyperphosphorylation of Epstein-Barr Virus Nuclear Antigen 2 Suppresses Its Function. Journal of Virology 78, 3542-3552. Zeng, Y., Middeldorp, J., Madjar, J.J., and Ooka, T. (1997). A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239, 285-295. Zhou, S., Du, X., Xie, J., and Wang, J. (2017). Interleukin-6 regulates iron-related proteins through c-Jun N-terminal kinase activation in BV2 microglial cell lines. PLoS One 12, e0180464. Zuo, J., Thomas, W.A., Haigh, T.A., Fitzsimmons, L., Long, H.M., Hislop, A.D., Taylor, G.S., and Rowe, M. (2011). Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathog 7, e1002455. zur Hausen, H., O'Neill, F.J., Freese, U.K., and Hecker, E. (1978). Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272, 373-375. zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Santesson, L. (1970). EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79056 | - |
dc.description.abstract | EB病毒(Epstein-Barr virus, EBV)是一具有致癌性的病毒,跟許多的人類疾病有高度的相關性,包含了巴氏淋巴瘤 (Burkitt’s lymphoma)、霍杰金氏症 (Hodgkin’s disease) 、鼻咽癌( Nasopharyngeal Carcinoma, NPC) 、移植後淋巴組織增生症(Post-transplant lymphoproliferative disorder, PTLD)、瀰漫型大B 細胞淋巴癌(Diffuse large B cell lymphoma, DLBCL)等。在體外系統中,EB病毒可感染人類B細胞,使其不朽化成具持續增生能力的類淋巴母芽細胞株(lymphoblastoid cell line, LCL),而LCL的基因表現模式跟PTLD有非常多相似性,因此LCL可作為在體外系統中研究EB病毒致癌機轉的模型。
實驗室先前利用cDNA微陣列分析CD19+初級B細胞及LCLs基因表現的變化情形,如預期地,LCLs與初級B細胞的基因表現呈現了許多不同,而在其中,一分化簇標記分子—CD300a的表現量在LCLs中顯著的升高。並且CD300a表現量上升的情形只在EB病毒感染時發生,而非利用其他刺激物活化B細胞時,如anti-CD40/ IL4, poly I:C, 或LPS。由於CD300a本質是一抑制性受體,在免疫細胞中調控許多免疫反應。因此本研究欲探討在EB病毒感染B細胞後,是如何調控CD300a以及CD300a在其中扮演的生理功能。 實驗結果顯示,在EB病毒感染B細胞後,會透過EBNA2 (EBV nuclear antigen 2)誘發CD300a的表現。根據螢光酵素報導分析的實驗結果,EBNA2會增加CD300a啟動子活性。由於在細胞中EBNA2通常藉由跟轉錄因子RBP-Jκ互動,而達成調控EBNA2的標的基因表現,我們利用RNA干擾抑制RBP-Jκ在LCLs的表現,發現CD300a表現量有下降的情形。暗示了RBP-Jκ應該是參與在EBNA2所誘發的CD300a調控。 為了探討CD300a在LCLs的生理功能,我們在LCLs中利用RNA干擾抑制CD300a的表現。實驗結果顯示,抑制CD300a會使EB病毒進入溶裂期,暗示CD300a具有抑制EB病毒再活化的功能。且在螢光酵素報導分析中,實驗結果顯示,CD300a可以抑制Zta promoter (Zp)活性。因此我們認為CD300a可透過抑制Zp阻止EB病毒的再活化。另外本研究也發現利用RNA干擾的方式抑制CD300a後,會誘使細胞凋亡(apoptosis)及增加細胞激素IL-6 (Interleukin 6)的表現。而為了探討CD300a是透過何種路徑調控其下游訊號,根據RNA干擾的實驗結果,我們發現抑制CD300a同時也會造成JNK (c-Jun N-terminal kinase)、ATF2 (cAMP-dependent transcription factor)及Akt的磷酸化程度上升,並且抑制JNK磷酸化會降低抑制CD300a引起的EB病毒溶裂期蛋白表現,暗示CD300a可透過抑制JNK幫助EB病毒維持在潛伏期。而其餘磷酸化程度的變化對於EB病毒再活化及LCLs的生存的生理意義則有待討論。 | zh_TW |
dc.description.abstract | As a human oncogenic virus, Epstein-Barr virus (EBV) infection is associated with many human diseases, especially in B cells disorders, such as Burkitt’s lymphoma, Hodgkin’s disease, post-transplant lymphoproliferative disorder (PTLD), diffuse large B cell lymphoma (DLBCL) etc. In vitro, the oncogenecity of EBV can be evidenced by its ability of immortalizing primary B cells into unlimitedly proliferating lymphoblastoid cell lines (LCLs). There are so many similarities between LCL and PTLD. So, LCLs become the perfect in vitro model to study EBV carcinogenesis.
In our previous study, cDNA microarray is used to analyze the gene expression alteration between CD19+ primary B cells and LCLs. As expected, an array of genes display differentially between primary B cells and LCLs. Among them, a surface cluster of differentiation marker CD300a, mRNA expression is increased significantly in LCLs. Of interest, the up-regulation of CD300a only shows in B cells infected with EBV but not with other B cell stimulators, such as anti-CD40/ IL4, poly I:C, or LPS. So, we focus in the role of CD300a since it functions as an inhibitory receptor and involves in many regulation of immune activity in immune cells. In previous study, EBV nuclear antigen 2 (EBNA2) induces CD300a expression by transfection among the test viral genes, at transcriptional level. Data of luciferase reporter assay demonstrates that EBNA2 may up-regulate CD300a promoter activity. Usually, EBNA2 interacts with a cellular transcriptional factor RBP-Jκ to regulate gene expression. We find that RBP-Jκ is involved in EBNA2 mediated CD300a upregulation since knockdown of RBP-Jκ in LCL results in decrease of CD300a expression. In order to investigate the function of CD300a in LCLs, we knockdown CD300a by shRNA approach. We demonstrate that EBV enters the lytic cycle after knockdown of CD300a. It hints that CD300a inhibits EBV reactivation in LCL. Further, we show that CD300a can inhibit Zp (promoter of Zta) activity by luciferase reporter assay. We assume that CD300a inhibits EBV reactivation by repressing Zp activity. In addition, we find that cleavage of apoptotic protein PARP and IL-6 (Interleukin 6) production are increased when CD300a is knockdown. Mechanistically, we try to reveal which signaling pathways are triggered in CD300a downstream. According to results of CD300a knockdown, the phosphorylation level of JNK (c-Jun N-terminal kinase), ATF2 (cAMP-dependent transcription factor) and Akt is increased. The other data shows that inhibition of JNK activity restores the ability of CD300a to inhibit EBV reactivation. The biological meaning of this phosphorylation in EBV reactivation and LCL survival will be discussed. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:40:16Z (GMT). No. of bitstreams: 1 ntu-107-R05445112-1.pdf: 2690987 bytes, checksum: efab5591c84d9109fe5c65f783a0cb3c (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 中文摘要……………………………………………………………….…I
Abstract…………………………………………………………….........III 序論………………………………………………………………........…1 研究目的……………………………………………………………......12 實驗材料與方法……………………………………………………..…13 實驗結果………………………………………………………......……33 討論…………………………………………………………………..…41 圖表…………………………………………………………………..…48 附錄…………………………………………………………………..…68 參考文獻……………………………………………………………..…76 | - |
dc.language.iso | zh_TW | - |
dc.title | 探討CD300a在受EB病毒不朽化之類淋巴母芽細胞株中的表現及調控 | zh_TW |
dc.title | Expression and regulation of CD300a in Epstein-Barr virus-immortalized lymphoblastoid cell lines | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 顧家綺;董馨蓮;林素珍 | zh_TW |
dc.contributor.oralexamcommittee | ;; | en |
dc.subject.keyword | EB病毒,CD300a,EBNA2,Zp, | zh_TW |
dc.subject.keyword | EBV,CD300a,EBNA2,Zp, | en |
dc.relation.page | 86 | - |
dc.identifier.doi | 10.6342/NTU201802958 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-08-13 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 微生物學研究所 | - |
dc.date.embargo-lift | 2023-10-09 | - |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-2.pdf 目前未授權公開取用 | 2.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。